Thalidomide does not modify the prognosis of plasma cell leukemia patients: experience of a single center

Leuk Lymphoma. 2007 Jan;48(1):180-2. doi: 10.1080/10428190601007570.
No abstract available

Publication types

  • Clinical Trial
  • Letter

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Angiogenesis Inhibitors / adverse effects
  • Angiogenesis Inhibitors / therapeutic use
  • Female
  • Humans
  • Leukemia, Plasma Cell / diagnosis*
  • Leukemia, Plasma Cell / drug therapy*
  • Leukemia, Plasma Cell / mortality
  • Male
  • Maximum Tolerated Dose
  • Middle Aged
  • Multiple Myeloma / diagnosis
  • Multiple Myeloma / drug therapy
  • Multiple Myeloma / mortality
  • Prognosis
  • Salvage Therapy
  • Survival Analysis
  • Thalidomide / adverse effects
  • Thalidomide / therapeutic use*

Substances

  • Angiogenesis Inhibitors
  • Thalidomide